(Boursier.com) — Biocorp publishes an annual turnover which reaches 10,225 KE in 2021, up 20.9% compared to that of 2020 (8,456 KE) following the invoicing of the services provided for in the contracts signed with Novo and Merck. In 2021, other operating income amounted to 328.5 KE, compared to 20.5 KE in 2020. This variation is mainly explained by an increase in work in progress related to the registration of Mallya in the United States. States – the billing of a service to Sanofi is contractually provided for when obtaining this registration – and an increase in the subsidies received.
Operating expenses reached 10,416 K, up 3.3% compared to 2020, demonstrating good control of operating expenses. Taking these elements into account, the 2021 operating result is positive at 137.4 KE, against a negative result (1,605 KE) a year earlier.
The financial result for 2021, which shows a net amount of (89.6 KE) against (155.9 KE) in 2020, results mainly from interest on bond loans. The exceptional result for the financial year amounts to 48.5 KE, against 267 KE at 31/12/2020.
Taking into account all of these elements, BIOCORP stands out with a positive net result of 294.2 KE, against a loss of 1,242 KE in 2020.
At the end of the 2021 financial year, BIOCORP posted cash of 1,845.6 KE, compared to 4,971.9 KE at 31/12/2020.
©2022 Boursier.com